Clinical Trial: A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07174063) titled 'A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer' on Sept. 08.

Brief Summary: This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.

Study Start Date: Dec. 26, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Prostate Cancer (mCRPC)

Intervention: DRUG: JSB462

300 mg or 100 mg once a day (QD) with food

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Published by HT Digital Content Services with permission from Health Daily Digest....